Terms: = Ovarian cancer AND SOX2, MGC2413, 6657, ENSG00000181449, MCOPS3, P48431, ANOP3 AND Treatment
49 results:
1. Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors.
Muñoz-Galván S; Verdugo-Sivianes EM; Santos-Pereira JM; Estevez-García P; Carnero A
J Exp Clin Cancer Res; 2024 Feb; 43(1):57. PubMed ID: 38403587
[TBL] [Abstract] [Full Text] [Related]
2. Scoulerine promotes cytotoxicity and attenuates stemness in ovarian cancer by targeting PI3K/AKT/mTOR axis.
Wang F; Zhang Y; Pang R; Shi S; Wang R
Acta Pharm; 2023 Sep; 73(3):475-488. PubMed ID: 37708956
[TBL] [Abstract] [Full Text] [Related]
3. Primary ovarian Small Cell Carcinoma of Pulmonary Type: Analysis of 6 Cases and Review of 31 Cases in the Literatures.
Chen X; Liu HL; Wang JS; Zhao FH
Chin Med Sci J; 2023 Jun; 38(2):130-137. PubMed ID: 37286512
[TBL] [Abstract] [Full Text] [Related]
4. Regulation of self-renewal in ovarian cancer stem cells by fructose via chaperone-mediated autophagy.
Sohn EJ; Kim JH; Oh SO; Kim JY
Biochim Biophys Acta Mol Basis Dis; 2023 Aug; 1869(6):166723. PubMed ID: 37087023
[TBL] [Abstract] [Full Text] [Related]
5. Low-dose BPA and its substitute BPS promote ovarian cancer cell stemness via a non-canonical PINK1/p53 mitophagic signaling.
Yuan X; Chen K; Zheng F; Xu S; Li Y; Wang Y; Ni H; Wang F; Cui Z; Qin Y; Xia D; Wu Y
J Hazard Mater; 2023 Jun; 452():131288. PubMed ID: 36989771
[TBL] [Abstract] [Full Text] [Related]
6. TWEAK-Fn14-RelB Signaling Cascade Promotes Stem Cell-like Features that Contribute to Post-Chemotherapy ovarian cancer Relapse.
Holmberg R; Robinson M; Gilbert SF; Lujano-Olazaba O; Waters JA; Kogan E; Velasquez CLR; Stevenson D; Cruz LS; Alexander LJ; Lara J; Mu EM; Camillo JR; Bitler BG; Huxford T; House CD
Mol Cancer Res; 2023 Feb; 21(2):170-186. PubMed ID: 36214671
[TBL] [Abstract] [Full Text] [Related]
7. NANOG regulates epithelial-mesenchymal transition via AMPK/mTOR signalling pathway in ovarian cancer SKOV-3 and A2780 cells.
Yun H; Han GH; Kim J; Chung JY; Kim JH; Cho H
J Cell Mol Med; 2022 Oct; 26(20):5277-5291. PubMed ID: 36114703
[TBL] [Abstract] [Full Text] [Related]
8. Therapeutic Targeting of ovarian cancer Stem Cells Using Estrogen Receptor Beta Agonist.
He Y; Alejo S; Venkata PP; Johnson JD; Loeffel I; Pratap UP; Zou Y; Lai Z; Tekmal RR; Kost ER; Sareddy GR
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806169
[TBL] [Abstract] [Full Text] [Related]
9. In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6, and sox2.
du Manoir S; Delpech H; Orsetti B; Jacot W; Pirot N; Noel J; Colombo PE; Sardet C; Theillet C
J Pathol; 2022 Jul; 257(3):367-378. PubMed ID: 35302657
[TBL] [Abstract] [Full Text] [Related]
10. Exosome long non-coding RNA sox2-OT contributes to ovarian cancer malignant progression by miR-181b-5p/SCD1 signaling.
Lai Y; Dong L; Jin H; Li H; Sun M; Li J
Aging (Albany NY); 2021 Oct; 13(20):23726-23738. PubMed ID: 34690112
[TBL] [Abstract] [Full Text] [Related]
11. Development and in vitro characterisation of an induced pluripotent stem cell model of ovarian cancer.
Bindhya S; Sidhanth C; Krishnapriya S; Garg M; Ganesan TS
Int J Biochem Cell Biol; 2021 Sep; 138():106051. PubMed ID: 34343671
[TBL] [Abstract] [Full Text] [Related]
12. MET Expression and cancer Stem Cell Networks Impact Outcome in High-Grade Serous ovarian cancer.
Bååth M; Jönsson JM; Westbom Fremer S; Martín de la Fuente L; Tran L; Malander S; Kannisto P; Måsbäck A; Honeth G; Hedenfalk I
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34069138
[TBL] [Abstract] [Full Text] [Related]
13. The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix.
Pei X; Xiang L; Chen W; Jiang W; Yin L; Shen X; Zhou X; Yang H
Gynecol Oncol; 2021 Jun; 161(3):779-786. PubMed ID: 33888337
[TBL] [Abstract] [Full Text] [Related]
14. Preclinical evaluation of radiation therapy of
Cho EJ; Kim JK; Baek HJ; Kim SE; Park EJ; Choi BK; Kim TH; Shin DH; Lim YK; Deng CX; Kim SS
Int J Biol Sci; 2021; 17(3):689-701. PubMed ID: 33767581
[TBL] [Abstract] [Full Text] [Related]
15. iPSC-Derived Hereditary Breast cancer Model Reveals the
Portier L; Desterke C; Chaker D; Oudrhiri N; Asgarova A; Dkhissi F; Turhan AG; Bennaceur-Griscelli A; Griscelli F
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513753
[TBL] [Abstract] [Full Text] [Related]
16. Superparamagnetic Iron Oxide Nanoparticles Induce Ferroptosis of Human ovarian cancer Stem Cells by Weakening Cellular Autophagy.
Huang Y; Lin J; Xiong Y; Chen J; Du X; Liu Q; Liu T
J Biomed Nanotechnol; 2020 Nov; 16(11):1612-1622. PubMed ID: 33461653
[TBL] [Abstract] [Full Text] [Related]
17. Characteristics of CD133-Sustained Chemoresistant cancer Stem-Like Cells in Human ovarian Carcinoma.
Liu CL; Chen YJ; Fan MH; Liao YJ; Mao TL
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899775
[TBL] [Abstract] [Full Text] [Related]
18. A novel c-Kit/phospho-prohibitin axis enhances ovarian cancer stemness and chemoresistance via Notch3-PBX1 and β-catenin-ABCG2 signaling.
Fang CH; Lin YT; Liang CM; Liang SM
J Biomed Sci; 2020 Mar; 27(1):42. PubMed ID: 32169072
[TBL] [Abstract] [Full Text] [Related]
19. Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.
Connor EV; Saygin C; Braley C; Wiechert AC; Karunanithi S; Crean-Tate K; Abdul-Karim FW; Michener CM; Rose PG; Lathia JD; Reizes O
J Ovarian Res; 2019 Nov; 12(1):112. PubMed ID: 31735168
[TBL] [Abstract] [Full Text] [Related]
20. The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment.
Wang L; Li X; Mu Y; Lu C; Tang S; Lu K; Qiu X; Wei A; Cheng Y; Wei W
J Trace Elem Med Biol; 2019 Dec; 56():131-138. PubMed ID: 31466045
[TBL] [Abstract] [Full Text] [Related]
[Next]
